Aclarion (ACON) Revenue & Revenue Breakdown
Aclarion Revenue Highlights
Latest Revenue (Y)
$45.72K
Latest Revenue (Q)
$18.99K
Aclarion Revenue by Period
Aclarion Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2024-12-31 | $45.72K | -39.36% |
| 2023-12-31 | $75.40K | 24.75% |
| 2022-12-31 | $60.44K | 0.25% |
| 2021-12-31 | $60.29K | 23.93% |
| 2020-12-31 | $48.65K | 80.88% |
| 2019-12-31 | $26.90K | - |
Aclarion generated $45.72K in revenue during NA 2024, up -39.36% compared to the previous quarter, and up 170.00% compared to the same period a year ago.
Aclarion Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2025-03-31 | $18.99K | 85.60% |
| 2024-12-31 | $10.23K | -28.98% |
| 2024-09-30 | $14.41K | 31.32% |
| 2024-06-30 | $10.97K | 8.47% |
| 2024-03-31 | $10.11K | -26.69% |
| 2023-12-31 | $13.80K | -27.63% |
| 2023-09-30 | $19.07K | 11.67% |
| 2023-06-30 | $17.07K | -32.97% |
| 2023-03-31 | $25.47K | 13.10% |
| 2022-12-31 | $22.52K | 23.59% |
| 2022-09-30 | $18.22K | 70.68% |
| 2022-06-30 | $10.68K | 18.28% |
| 2022-03-31 | $9.03K | -24.64% |
| 2021-12-31 | $11.98K | 10.23% |
| 2021-09-30 | $10.87K | -57.59% |
| 2021-06-30 | $25.62K | 116.57% |
| 2021-03-31 | $11.83K | 18.63% |
| 2020-12-31 | $9.97K | -55.23% |
| 2020-09-30 | $22.27K | 171.48% |
| 2020-06-30 | $8.20K | - |
| 2020-03-31 | $8.20K | - |
Aclarion generated $18.99K in revenue during Q1 2025, up 85.60% compared to the previous quarter, and up 137.65% compared to the same period a year ago.
Aclarion Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| MSPR | MSP Recovery | $7.71M | $837.00K |
| NAOV | NanoVibronix | $2.28M | $494.00K |
| MOVE | Movano | $1.01M | $103.00K |
| SNGX | Soligenix | $119.37K | - |
| SILO | Silo Pharma | $72.10K | $18.03K |
| ACON | Aclarion | $45.72K | $18.99K |
| BJDX | Bluejay Diagnostics | - | - |
| BFRG | Bullfrog AI | - | - |
| NDRA | ENDRA Life Sciences | - | - |
| CMND | Clearmind Medicine | - | - |
| WINT | Windtree Therapeutics | - | - |